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Abstract
The genes regulating circulating levels of soluble gp130 (sgp130), the antagonist of the inﬂammatory response in
atherosclerosis driven by interleukin 6, are largely unknown. Aims of the present study were to identify genetic loci
associated with circulating sgp130 and to explore the potential association between variants associated with sgp130 and
markers of subclinical atherosclerosis. The study is based on IMPROVE (n= 3703), a cardiovascular multicentre study
designed to investigate the determinants of carotid intima media thickness, a measure of subclinical atherosclerosis. Genomic
DNA was genotyped by the CardioMetaboChip and ImmunoChip. About 360,842 SNPs were tested for association with
log-transformed sgp130, using linear regression adjusted for age, gender, and population stratiﬁcation using PLINK v1.07. A
p value of 1 × 10−5 was chosen as threshold for signiﬁcance value. In an exploratory analysis, SNPs associated with sgp130
were tested for association with c-IMT measures. We identiﬁed two SNPs signiﬁcantly associated with sgp130 levels and
24 showing suggestive association with sgp130 levels. One SNP (rs17688225) on chromosome 14 was positively associated
with sgp130 serum levels (β= 0.03 SE= 0.007, p= 4.77 × 10−5) and inversely associated with c-IMT (c-IMTmean–max β=
−0.001 SE= 0.005, p= 0.0342). Our data indicate that multiple loci regulate sgp130 levels and suggest a possible common
pathway between sgp130 and c-IMT measures.
Introduction
The soluble gp130 (sgp130) is a master regulator of
cytokine-mediated inﬂammatory, regenerative, and pro-
liferative effects [1–3]. Three main sgp130 isoforms, with
molecular weights between 50 and 110 KDa, can be
detected in the circulation: sgp130-RAPS [4], sgp130-E10
[5], and full length sgp130 [6] produced by alternative
splicing, alternative intronic polyadenylation [5], and
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shedding of the membrane gp130 receptor in a cell speciﬁc
manner [3]. Biological assays commonly used to measure
sgp130 do not differentiate among these three isoforms.
The main role of circulating sgp130 is anti-inﬂammatory.
Sgp130 has a high afﬁnity (1 mM) for IL6:sIL6R, the
complex that drives the pro-inﬂammatory and the pro-
atherogenic IL6 trans-signaling pathway [7, 8]. Binding of
sgp130 to IL6:sIL6R results in neutralization of the com-
plex [9] thus blunting the inﬂammatory response. It was
recently shown in in vitro condition that the full length
sgp130 is the most potent inhibitor of IL6 trans-signaling
[3]. A recombinant form of sgp130 (sgp130Fc) has been
shown to be exert an atheroprotective effect in a mouse
experimental model of atherosclerosclerosis [10] and
potentially able to antagonize the pro-inﬂammatory effect
driven by IL11 trans-signaling [11].
Clinical [12] and experimental evidence [10, 13] suggest
causality of IL6 trans-signaling on the inﬂammatory
response in atherosclerosis and data from our group indicate
that an excess of the circulating IL6:sIL6R over the ternary
IL6:sIL6R:sgp130 complex increases the risk for future
cardiovascular (CV) events [14].
The genes regulating sgp130 levels are largely unknown.
One single-nucleotide polymorphism (rs2228044) in
GP130 (chromosome 5) encoding an amino acid change
Gly148Arg, has been shown to be associated with lower
sgp130 circulating levels [15] and a reduced risk of myo-
cardial infarction [16]. Given the central role of sgp130 in
orchestrating the inﬂammatory response in atherosclerosis,
knowledge of the genes regulating sgp130 circulating levels
might provide novel insights on the mechanisms underlying
its synthesis and release and also suggest if sgp130 might
represent a novel therapeutic moiety to modulate the
inﬂammatory response in atherosclerosis.
The aim of the present study was to identify SNPs
associated with serum levels of sgp130, using genetic data
from the carotid Intima Media Thickness (c-IMT) and c-
IMT Progression as Predictors of Vascular Events
(IMPROVE), a high cardiovascular risk European popula-
tion study. In secondary analysis, genetic variants asso-
ciated with sgp130 were tested for association with c-IMT,
a measure of vascular wall remodeling indicative of sub-
clinical atherosclerosis.
Results
Table 1 summarizes the characteristics of the IMPROVE
study participants included in the present study according to
sgp130 quartiles. High sgp130 levels were more often
observed in women and in study participants with diabetes
and hypercholesterolemia.
Table 1 Baseline characteristics
of the IMPROVE study
participants included in the
study according to the sgp130
quartiles.
Sgp130 Q1
(n= 859)
Sgp130 Q2
(n= 860)
Sgp130 Q3
(n= 860)
Sgp130 Q4
(n= 860)
Age (years) 64.52 ± 5.19 64.69 ± 5.47 63.88 ± 5.41 63.63 ± 5.57
Male N (%) 485 (27.67) 432 (24.64) 441 (25.16) 395 (22.53)
BMI (kg/cm2) 27.11 ± 4.25 27.17 ± 4.1 27.33 ± 4.25 27.46 ± 4.46
Waist/hip (cm) 0.92 ± 0.09 0.92 ± 0.08 0.92 ± 0.09 0.91 ± 0.08
SBP (mmHg) 141.47 ± 19.37 142.77 ± 18.35 142.08 ± 18.77 141.58 ± 17.36
DBP (mmHg) 81.74 ± 10.07 82.13 ± 9.58 81.76 ± 9.81 82.27 ± 9.65
Risk factors for cardiovascular disease N (%)
Smoking 148 (17.23) 116 (13.49) 125 (14.53) 127 (14.77)
Hypercholesterolemia 658 (76.60) 661 (76.86) 668 (77.67) 692 (80.47)
Hypertension 712 (77.73) 743 (81.11) 733 (79.93) 723 (78.93)
Diabetes 228 (25.39) 226 (25.06) 256 (28.60) 255 (28.02)
Biochemical measurements
LDL-cholesterol (mmol/L) 3.54 ± 0.98 3.55 ± 1.03 3.53 ± 1.01 3.57 ± 1
Glucose (mmol/L) 5.97 ± 1.51 5.91 ± 1.58 5.93 ± 1.68 5.85 ± 1.75
Creatinine (micromol/L) 80.23 ± 17.26 81.27 ± 17.88 81.19 ± 17.76 80.94 ± 18.1
Inﬂammatory biomarkers
C reactive Protein (mg/L) 1.74 (0.73–3.45) 1.73 (0.71–3.47) 1.88 (0.74–3.61) 2.08 (0.89–3.93)
Sgp130 (ng/ml) 382.75 ± 53.84 507.30 ± 33.76 632.06 ± 40.73 837.08 ± 113.13
Missing values: BMI, n= 1; waist/hip ratio, n= 10; SBP and DBP, n= 4; diabetes, n= 54; LDL-
cholesterol, n= 68; glucose, n= 7; creatinine, n= 7; C-reactive protein, n= 2
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, LDL low-density
lipoprotein
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Genetic variants associated with serum sgp130
levels
Table 2 summarizes the SNPs with signiﬁcant or suggestive
associations with serum sgp130 levels after adjustment for
age, sex, and population structure. Supplementary Fig. II
displays the Manhattan plot summarizing the results of the
association analysis.
According to the signiﬁcance threshold value we chose,
only two SNPs were signiﬁcantly associated with circulat-
ing sgp130 levels: rs10935473 (on chromosome 3, Fig. 1a)
and rs1929666 (on chromosome 10, Fig. 1b).
Rs10935473 is in moderate linkage disequilibrium (LD)
(r2 : 0.67) with rs9858592 located in the ST3GAL6-anti
sense RNA 1 (ST3GAL6AS1) (Table 2). The GTEx
expression panel reports the effect allele (EA) at both SNPs
as associated with a lower expression of the long noncoding
RNA ST3GAL6 in a large panel of tissues such as the
adipose tissue, the heart, and the arterial wall (https://
gtexportal.org/home/snp/rs10935473) and with lower levels
of circulating sgp130.
Among the SNPs potentially associated with
sgp130 serum levels, we have identiﬁed a potentially
functional SNP, rs2228043, which encodes a missense
Table 2 SNPs associated with circulating serum sgp130 levels.
Chr SNP EA Frequency (%) β SE P Gene Contig/gene
sequence
Functional
consequence
Signiﬁcant (p value < 1 × 10−5)
3 rs10935473 T 47 −0.014 0.003 9.45 × 10−6 Unknown NT_005612.17 –
10 rs1929666 T 10 0.025 0.005 1.63 × 10−6 LOC105378515 NT_030059.14 Intronic SNP
Suggestive (p value < 1 × 10−4)
1 rs74760246 T 7 −0.028 0.006 1.21 × 10−5 CRB1 NG_008483.2 Intronic SNP
1 rs3006246 A 26 −0.015 0.003 4.31 × 10−5 NR5A2 NM_001276464.1 Intronic SNP
3 rs9858592 C 49 −0.013 0.003 5.62 × 10−5 ST3GAL6AS1 NR_046683.1 Intronic SNP
5 rs2228043 C 13 0.019 0.004 9.81 × 10−5 GP130 NM_001190981.1 NS aa change
L397V
7 rs2622168 A 3 0.041 0.010 4.37 × 10−5 DPP6 NT_007933.16 Intronic SNP
7 rs73063812 C 5 −0.030 0.007 7.27 × 10−5 DGKB NM_004080.2 3′UTR
7 rs11767669 A 15 −0.018 0.004 3.92 × 10−5 Unknown NT_007933 –
8 rs3087409 A 5 0.029 0.007 2.70 × 10−5 WRN NG_008870.1 Intronic SNP
9 rs12379461 A 36 −0.013 0.003 9.25 × 10−5 OBP2B NT_008470.20 –
9 rs16932962 C 6 0.027 0.007 9.09 × 10−5 TTC39B NM_001168339.1 Intronic SNP
10 rs1972396 T 3 0.035 0.008 7.72 × 10−5 CACNB2 NM_000724.3 Intronic SNP
11 rs1681503 T 2 0.043 0.010 4.62 × 10−5 ARAP1 NM_001040118.2 Intronic SNP
12 rs6582091 A 3 −0.039 0.010 8.87 × 10−5 TRHDE NM_013381.2 Intronic SNP
13 rs11069292 G 15 −0.019 0.004 4.06 × 10−5 LOC105370328 XR_931670 Intronic SNP
13 rs9529615 A 37 0.013 0.003 6.40 × 10−5 Unknown NT_024524 –
14 rs17688225 A 5 0.030 0.007 4.77 × 10−5 Unknown NC_000014.7
14 rs12886000 T 15 0.017 0.004 6.93 × 10−5 LOC107984706 XR_001750873.1 –
17 rs1872083 T 30 −0.014 0.003 4.63 × 10−5 SDK2 NM_001144952.1. Intronic SNP
17 rs4795780 T 21 0.015 0.003 6.10 × 10−5 ASIC 2 NM_001144952.1. Intronic SNP
17 rs2955617 A 32 0.014 0.003 2.43 × 10−5 Unknown NT_010718.17 –
19 rs3813774 A 6 −0.028 0.006 4.63 × 10−5 FBN3 NM_001321431.1 S aa change C643C
20 rs4809631 C 17 −0.019 0.004 1.75 × 10−5 ZMYND8 NM_001281771 Intronic SNP
20 rs35425776 A 97/3 0.038 0.008 1.09 × 10−5 Unknown NT_011362.11 –
20 rs808682 T 75/25 −0.015 0.003 8.78 × 10−5 Unknown NT_011387 –
Chr chromosome, EA effect allele, S synonymous, NS non synonymous, Aa amino acid, CRB1 crumbs 1, cell polarity complex component, NR5A2
nuclear receptor subfamily 5 group A member 2, ST3GAL6AS1 ST3GAL6 antisense RNA 1, GP130 glycoprotein 130, L Leucin, V Valin, DPP6
dipeptidyl peptidase like 6, DGKB diacylglycerol kinase beta, WRN Werner syndrome RecQ like helicase, OBP2B odorant binding protein 2B,
TTC39B tetratricopeptide repeat domain 39B, 3′UTR 3′ untraslated region, LOC uncharacterized locus, CACNB2 calcium voltage-gated channel
auxiliary subunit beta 2, ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1, TRHDE thyrotropin releasing hormone
degrading enzyme, SDK2 sidekick cell adhesion molecule 2, ASIC2 acid sensing ion channel subunit 2, SLC14A2 solute carrier family 14 member
2, FBN3 ﬁbrillin 3, C cysteine, ZMYND8 zinc ﬁnger MYND-type containing 8
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amino acid change L370V in GP130 (chromosome 5). This
SNP maps to the coding region of GP130 isoform 1
(NM_002184.4) (exon 10) and to the 3′UTR of GP130
isoform 2 (NM_175767.3), known also as gp130-RAPS.
The GTEx expression panel reports a lower tissue gp130
expression in the tibial nerve in the heterozygote GC, while
too few observations are available for the GG genotype
group to deﬁne the direction of the effect (https://www.
gtexportal.org/home/snp/rs2228043).
Only two of the SNPs identiﬁed in the present study have
formerly been associated with the risk of inﬂammatory and
CV diseases: rs74760246 (chromosome 1), in the intronic
region of CRB1, is in strong LD (r2 ≥ 0.8) with rs1421389
and rs10494757 mapping at DENNB1, a gene associated
with the risk of chronic inﬂammatory diseases [17, 18];
rs3087409 (chromosome 8) at WRN, an intronic SNP in
full LD with a variant previously associated with premature
aging and with the risk of myocardial infarction and
stroke [19].
The other SNPs identiﬁed as suggestively associated
with sgp130 circulating levels can be grouped in SNPs
mapping at genetic loci previously associated with the
regulation of cholesterol and glucose metabolism such as
rs3006246 (chromosome 1) in NR5A2, also known as liver
receptor homolog 1 [20], rs3813774 in FBN3 (chromosome
19) an SNP causing a synonymous amino acid change and
Fig. 1 Regional association
plot of chromosome 3 and
chromosome 10 (Chr10) loci.
Regional association plot of
chromosome 3 (Chr3) (Panel A)
and chromosome 10 (Chr10)
(Panel B) loci. The diamond
(shown in purple) corresponds to
the index SNP identiﬁed as
associated with sgp130,
rs10935473 on chromosome 3,
and rs1929666 on chromosome
10. The SNPs in the region are
represented by circles. The color
of the circle exempliﬁes the
degree of LD with the index
SNP (see R2 values on the right
of the ﬁgure).
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rs73063812 (chromosome 7) in DKGB 3′UTR all inversely
associated with circulating sgp130 levels and rs1681503
(chromosome 11) in ARAP1 [21] and rs16932962 (chro-
mosome 9) in TTC39B positively associated with sgp130.
TTC39B has unknown function, however SNPs mapping at
this gene, in low LD (r2) with the SNPs identiﬁed here have
been associated with low HDL levels [22]. Finally,
rs6582091 (chromosome 12) in TRHDE a metallopeptidase
1 involved in the degradation of thyrotropin differentially
expressed in the perivascular and subcutaneous fat [23].
In addition, some suggestive SNPs map to loci encoding
auxiliary subunits of membrane ion channels, such as
rs2622168 (chromosome 7) in DPP6 (a dipeptidyl peptidase
that enhances expression and kinetics of voltage-gated K(+)
channels on muscular cells and neurons [24]) and
rs1972396 (chromosome 10) in CACNB2 (encoding a
subunit of calcium voltage-gated [25]) and rs4795780 at
ASIC 2 (chromosome 17) (encoding an amiloride-sensitive
sodium channel).
Taken together the 26 SNPs explained 11% of the var-
iance in circulating sgp130 levels, while each single SNP
explained less than 1% of the total variance.
Secondary analysis: association of the SNPs
associated with sgp130 with c-IMT measures
We performed an exploratory analysis where the SNPs with
signiﬁcant or suggestive associations with sgp130 were
tested for association with measures of c-IMT at baseline.
Three SNPs were nominally associated (p value < 0.05) with
measures of c-IMT as shown in Table 3. After adjustment for
age, sex, multidimensional scaling (MDS), and sgp130, only
rs17688225 on chromosome 14 remained negatively associated
with c-IMT measures at baseline (c-IMTmean: β=−0.010
SE= 0.005, p= 0.0251; c-IMTmean–max: β=−0.010 SE=
0.005, p= 0.0347; c-IMTmax: β=−0.025 SE= 0.009,
p value= 0.0049). Of interest, this allele is positively asso-
ciated with levels of sgp130 (β= 0.030 SE= 0.007,
p value= 4.77 × 10−5).
Discussion
This is the ﬁrst study presenting a systematic analysis of the
genetic variants associated with circulating sgp130 in a
large European population. We have identiﬁed multiple
SNPs, each one exerting a small effect on circulating levels
of sgp130. Most of the SNPs identiﬁed showed a weak
association with circulating levels of sgp130 and only two
SNPs (rs10935473 and rs1929666) surpassed the pre-
speciﬁed signiﬁcance threshold level. The large number of
variants regulating sgp130 probably reﬂect its pleiotropic
effect in a large spectrum of chronic inﬂammatory and
autoimmune diseases [26] and has been also observed in
other studies analyzing the genetic basis of complex phe-
notypes [27].
Our results indicate that a genetic locus on chromosome
3 might be relevant for the regulation of circulating levels of
sgp130. One of the SNPs identiﬁed in our study
(rs9858592) is in strong LD (r2 > 0.8) with two intronic
ST3GAL6AS1 SNPs (rs4857414 and rs12635955) pre-
viously reported on the NCBI database to be associated with
circulating sgp130 (https://www.ncbi.nlm.nih.gov/projects/
SNP/GaPBrowser_prod/callGaPBrowser2.cgi?snp=
828588&aid=3748). ST3GAL6AS1 codes for a long non-
coding RNA, possibly involved in the regulation of the
expression of a sialyltransferase, ST3GAL6 [28]. Sialylation
contributes to regulation of cell adhesion and is recognized
as one of the cellular mechanisms promoting atherosclerosis
[29]. The role of the antisense RNA identiﬁed as a regulator
of sgp130 has not been deﬁned in atherosclerosis.
Rs9858592 is in moderate LD (r2= 0.69) with rs865474,
another SNP in ST3GAL6 previously reported as causally
associated with body mass index [30].
Individuals with metabolic syndrome demonstrated ele-
vated sgp130 levels [31] and additional nine SNPs located
at genetic loci involved in the regulation of glucose and
lipid metabolism, as well as associated with obesity, have
been identiﬁed as potentially associated with circulating
sgp130 levels in the present study. Taken together our data
suggest that variants regulating sgp130 levels are also
involved in the regulation of cardiometabolic phenotypes
where a low-grade inﬂammation is commonly observed.
Among the SNPs showing a suggestive association with
sgp130 we report rs2228043, in GP130. Rs2228043 is in
full LD (r2= 0.99) with rs2228044. The EA at both SNPs
associates with higher sgp130 levels [15]. Rs2228043
Table 3 SNPs associated with c-IMT measures at baseline.
Model 1 Model 2
β SE p value β SE p value
c-IMTmean
rs17688225 −0.010 0.005 0.0327 −0.010 0.005 0.0251
rs4809631 −0.003 0.003 0.2179 −0.003 0.003 0.2636
c-IMTmax
rs17688225 −0.024 0.009 0.0074 −0.025 0.009 0.0049
rs4809631 −0.010 0.005 0.0381 −0.010 0.005 0.0537
c-IMTmean–max
rs17688225 −0.010 0.005 0.0422 −0.010 0.005 0.0342
rs4809631 −0.004 0.003 0.1525 −0.004 0.003 0.1819
rs3813774 −0.007 0.005 0.1473 −0.006 0.005 0.1772
β beta, SE standard error
Model 1: Adjusted for age, sex and latitude
Model 2: Model 1+ sgp130
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introduces a Leu397Val amino acid substitution in exon 10
while rs2228044 introduces a Gly148Arg amino acid sub-
stitution in exon 5, both in the extracellular part of the
protein which is formed by six ﬁbronectin-type III-like
domains [32] (https://www.uniprot.org/uniprot/P40189).
Exon 5 belongs to the second ﬁbronectin-type III-like
domain, a region contributing to regulate the efﬁciency of
the binding to circulating cytokine [33, 34]; while exon 10,
is proximal to the gp130 transmembrane region and
necessary for an effective gp130 signal transduction [35].
The mechanisms underlying the association of these genetic
variants with circulating sgp130 are unknown and deserve
further investigations. However, one might speculate that
these mutations may change the conformation and/or sta-
bility of the extracellular domain and by doing so they may
favor the shedding of the membrane-bound gp130.
Another group of SNPs possibly associated with sgp130
map at loci encoding regulatory subunits of voltage-gated
channels previously associated with the risk of cardiac
arrhythmias [36–38], neurodegenerative [39] and psychia-
tric disorders [40, 41], and telomere length [42]. Functional
studies have indicated that a cross-talk between the
IL6 signaling and voltage-gated channels participates in the
regulation of nociception in response to trauma or inﬂam-
matory disease [43] such as rheumatoid arthritis [44].
In our secondary analyses we have identiﬁed one SNP
associated negatively with c-IMT measures at baseline and
positively with levels of sgp130. The candidate gene at this
locus is unclear. The opposite direction of these associations
is consistent with a protective effect of sgp130 in athero-
sclerosis, which has previously been demonstrated: high
levels of sgp130 exert a protective effect on the athero-
sclerotic process as shown by data obtained in a mouse
experimental model of atherosclerosis where treatment with
recombinant sgp130 was associated with regression of
atherosclerotic lesions [10].
This study has several limitations. It is an observational
study and as such we cannot provide insights on the
mechanisms underlying the observed associations, nor can
the causality of sgp130 on atherosclerosis be assessed. The
IMPROVE is a multicentre study where study participants
had high risk for CV events, which hampers the general-
ization of our results to the general population. The
important strengths of the current study are the use of
standardized methods across the recruitment sites and
genetic data with prior probability of associations with
cardiometabolic, immune, or inﬂammatory conditions.
In conclusion, we report here the ﬁrst systematic inves-
tigation of the genetic variants associated with circulating
levels of sgp130, the natural antagonist of the IL6 trans-
signaling. Our results indicate that multiple genetic loci
participate in the regulation of sgp130 levels, some possibly
overlap with those regulating c-IMT measures and highlight
a number of cardiometabolic pathways in which sgp130
might participate. This study suggests that investigation of
the causality of sgp130 in atherosclerosis would be of value,
as this is a prerequisite for identifying novel molecular drug
targets.
Materials/subjects and methods
Study population
The IMPROVE study is a European multicentre, long-
itudinal, observational study, fully described elsewhere
[45]. Brieﬂy, from March 2004 to April 2005 seven dif-
ferent centers in ﬁve European Countries (Italy, France, The
Netherlands, Sweden, and Finland) recruited 3711 study
participants (age 54–79 years) with at least three vascular
risk factors [i.e., men, women at least 5 years after meno-
pause, dyslipidemia, hypertension, diabetes, smoking, and
family history of CV disease] but without diagnosed CV
and/or cerebrovascular disease. At enrollment, study parti-
cipants ﬁlled in an extensive questionnaire on medical
history, life style habits, CV risk factors, co-morbidities,
current, and past medications and underwent a medical
assessment where anthropometric measures and blood
pressure were measured and recorded. Smoking was deﬁned
as current smoking. Hypertension was deﬁned as self-
reported and/or diastolic blood pressure (DBP) ≥ 90 mmHg
and/or systolic blood pressure (SBP) ≥ 140 mmHg and/or
treatment with antihypertensive drugs; diabetes was deﬁned
as self-reported and/or blood glucose level ≥ 7 mmol/L and/
or treatment with insulin or oral hypoglycaemic drugs.
Hypercholesterolemia was deﬁned as LDL cholesterol
≥ 4.13 mmol/L and/or treatment with cholesterol lowering
drugs.
Blood samples were collected after an overnight fast and
stored at −80 °C until analysis.
A detail description of the protocol, the validation and
the precision of carotid ultrasound measurements has been
reported elsewhere [45–47]. Ultrasonographic measures of
the carotid arteries were recorded at baseline by measuring
four consecutive segments at the far wall of from each
carotid artery. Data from the eight segments in each patient
were averaged to estimate the c-IMTmean, c-IMTmax, and c-
IMTmean–max. Data are expressed in mm.
Selection of SNPs, genotyping, and quality control
procedure
Genomic DNA from IMPROVE study participants was
genotyped with two genotyping arrays, the CardioMeta-
boChip 200k and the ImmunoChip, each one containing
~200,000 genetic variants [48, 49]. The CardioMetaboChip
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200 K is a custom Illumina iSelect genotyping array
including genetic variants mapping in genetic regions
identiﬁed in genome-wide association (GWA) studies as
potentially relevant for cardiometabolic diseases [49]. The
Immonochip is a custom Illumina Inﬁnium HD array
designed to densely genotype immune-mediated diseases
using loci identiﬁed by GWA studies [48].
Standard quality control procedures for genetic data were
conducted on the individual genotyping chip as well as the
combined dataset. MDS components were calculated using
PLINK v1.07 [50] to identify possible non-European ethnicity
and to enable adjustment for population structure. Three MSD
components were found to be informative (MSD1, MSD2,
and MSD3). One-hundred and eleven study participants did
not have genotype data. SNPs were excluded if deviation
from Hardy–Weinberg equilibrium (p < 0.0000001), call rate
<95% or minor allele frequency (MAF) <1% was detected.
Subjects were excluded due to cryptic relatedness, ambiguous
sex or if they were identiﬁed as outliers by MDS analysis
(n= 86). After exclusions, a total of 360,842 SNPs and
3439 study participants were available for genetic analysis.
Supplementary Fig. I summarizes the exclusion criteria
applied in the present study and the total number of study
participants included in the analysis.
Sgp130 measurement
Serum samples were missing for 67 subjects. Serum levels
of sgp130 were measured by the Human sgp130 DuoSet
ELISA development kit (#DY228) provided by R&D Sys-
tems® (R&D systems Minneapolis, MN, USA) using a
protocol previously reported [51].
Statistical analysis
Continuous variables with a normal distribution are pre-
sented as mean ± SD while variables with a skewed dis-
tribution are presented as median and interquartile ranges.
Categorical data are presented as n (%). Baseline char-
acteristics of the study participants were reported according
to sgp130 serum quartiles: quartile boundaries (ng/ml) Q1:
≤452; Q2: >452 to ≤566; Q3: >566 to ≤705; Q4: >705.5.
Sgp130 serum levels (ng/ml) were not normally dis-
tributed therefore they were log transformed for the genetic
association analysis. All genetic variants present in the
combined CardioMetabo-Immuno chip were tested for
association with log transformed serum sgp130 levels using
a linear regression analysis under the assumption of an
additive model of inheritance. A p value ≤ 1 × 10−5 was
chosen as the a priori signiﬁcance threshold. A suggestive
association threshold was deﬁned as p value > 1 × 10−5 ≤
1 × 10−4. Two SNP pairs showed a high pairwise LD (r2 ≥
0.8), rs9898140/rs4795780, and rs12884892/rs12886000,
therefore only one SNP in the pair is reported in the ana-
lysis. Results are reported as beta (β) and standard error
(SE) after adjustment for age, gender, and population
structure (using MDS1, MDS2, and MDS3). MDS1 is
highly correlated with latitude (r= 0.92, p < 0.0001). The
variance in sgp130 levels explained by each SNP was
estimated by partial r2, while the total variance explained by
all the identiﬁed SNPs was estimated by r2.
The potential effect of SNP genotype on tissue expres-
sion (eQTL) of genes is reported from data published on the
GTEx (https://gtexportal.org/home/) [52].
In a secondary analysis, we attempted to investigate if
SNPs potentially relevant in the regulation of circulating
sgp130 levels were associated with log transformed c-IMT
baseline measures using the general linear model. We used
two different models: model 1 adjusted for age, sex, and
MDS1-3 and model 2 as per model 1, with addition of
sgp130 as covariate. Results are reported as β and SE.
Standard epidemiological analyses were performed using
SAS version 9.4 (SAS Institute, Cary, NC). Genetic asso-
ciation analysis was performed using Plink v1.07 [50].
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